MARKET

QTTB

QTTB

Q32 BIO INC
NASDAQ
4.240
+0.370
+9.56%
After Hours: 4.320 +0.08 +1.89% 19:59 02/06 EST
OPEN
3.920
PREV CLOSE
3.870
HIGH
4.700
LOW
3.920
VOLUME
411.34K
TURNOVER
--
52 WEEK HIGH
6.37
52 WEEK LOW
1.345
MARKET CAP
52.17M
P/E (TTM)
-1.2294
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at QTTB last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at QTTB last week (0119-0123)?
Weekly Report · 01/26 09:30
Weekly Report: what happened at QTTB last week (0112-0116)?
Weekly Report · 01/19 09:34
Weekly Report: what happened at QTTB last week (0105-0109)?
Weekly Report · 01/12 09:33
Weekly Report: what happened at QTTB last week (1229-0102)?
Weekly Report · 01/05 09:31
Weekly Report: what happened at QTTB last week (1222-1226)?
Weekly Report · 12/29/2025 09:30
Weekly Report: what happened at QTTB last week (1215-1219)?
Weekly Report · 12/22/2025 09:30
Q32 Bio Mark Iwicki Withdraws Resignation From Q32 Bio Board; Mark Iwicki To Remain Chair Of Board
Benzinga · 12/19/2025 21:57
More
About QTTB
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity. The Company is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb - CR1 fusion protein which demonstrated preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.

Webull offers Q32 Bio Inc stock information, including NASDAQ: QTTB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QTTB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QTTB stock methods without spending real money on the virtual paper trading platform.